Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Stock analysts at William Blair lowered their FY2024 earnings per share (EPS) estimates for Apellis Pharmaceuticals in a research note issued to investors on Tuesday, November 5th. William Blair analyst L. Hanbury-Brown now anticipates that the company will post earnings per share of ($1.71) for the year, down from their prior estimate of ($1.25). William Blair has a "Outperform" rating on the stock. The consensus estimate for Apellis Pharmaceuticals' current full-year earnings is ($1.40) per share. William Blair also issued estimates for Apellis Pharmaceuticals' Q4 2024 earnings at ($0.41) EPS, Q1 2025 earnings at ($0.37) EPS, Q2 2025 earnings at ($0.30) EPS, Q3 2025 earnings at ($0.24) EPS, Q4 2025 earnings at ($0.16) EPS and FY2025 earnings at ($1.07) EPS.
Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.14). The company had revenue of $196.83 million during the quarter, compared to analysts' expectations of $200.00 million. Apellis Pharmaceuticals had a negative return on equity of 138.32% and a negative net margin of 52.99%. Apellis Pharmaceuticals's quarterly revenue was up 78.3% compared to the same quarter last year. During the same period last year, the firm posted ($1.17) earnings per share.
A number of other research firms have also recently commented on APLS. Scotiabank lowered their price target on shares of Apellis Pharmaceuticals from $35.00 to $30.00 and set a "sector perform" rating on the stock in a report on Wednesday. Bank of America lowered their target price on Apellis Pharmaceuticals from $61.00 to $47.00 and set a "buy" rating on the stock in a research note on Wednesday. Piper Sandler cut their price target on Apellis Pharmaceuticals from $40.00 to $32.00 and set a "neutral" rating for the company in a research note on Wednesday. The Goldman Sachs Group lowered their price objective on Apellis Pharmaceuticals from $71.00 to $36.00 and set a "buy" rating on the stock in a research note on Wednesday. Finally, Wells Fargo & Company cut their target price on shares of Apellis Pharmaceuticals from $43.00 to $30.00 and set an "equal weight" rating for the company in a research report on Wednesday. Six investment analysts have rated the stock with a hold rating, eleven have given a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, Apellis Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $51.06.
Check Out Our Latest Stock Report on Apellis Pharmaceuticals
Shares of APLS stock opened at $28.74 on Friday. The company has a quick ratio of 4.18, a current ratio of 5.08 and a debt-to-equity ratio of 1.73. Apellis Pharmaceuticals has a 52 week low of $24.34 and a 52 week high of $73.80. The firm's 50-day simple moving average is $31.19 and its two-hundred day simple moving average is $37.14.
Several hedge funds have recently added to or reduced their stakes in the company. KBC Group NV raised its holdings in shares of Apellis Pharmaceuticals by 34.8% during the 3rd quarter. KBC Group NV now owns 2,632 shares of the company's stock valued at $76,000 after buying an additional 679 shares in the last quarter. GSA Capital Partners LLP purchased a new position in shares of Apellis Pharmaceuticals during the third quarter worth approximately $824,000. Wolverine Asset Management LLC purchased a new position in shares of Apellis Pharmaceuticals during the third quarter worth approximately $27,000. State of New Jersey Common Pension Fund D lifted its holdings in shares of Apellis Pharmaceuticals by 10.1% in the 3rd quarter. State of New Jersey Common Pension Fund D now owns 49,795 shares of the company's stock worth $1,436,000 after acquiring an additional 4,554 shares during the last quarter. Finally, Assetmark Inc. boosted its stake in shares of Apellis Pharmaceuticals by 6.6% in the 3rd quarter. Assetmark Inc. now owns 46,065 shares of the company's stock valued at $1,329,000 after purchasing an additional 2,852 shares in the last quarter. Institutional investors own 96.29% of the company's stock.
In other Apellis Pharmaceuticals news, Director A. Sinclair Dunlop sold 37,000 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $36.23, for a total transaction of $1,340,510.00. Following the completion of the sale, the director now directly owns 100,000 shares in the company, valued at $3,623,000. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 6.80% of the company's stock.
Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Apellis Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Apellis Pharmaceuticals wasn't on the list.
While Apellis Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.